Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil

Sponsors

Lead Sponsor: Fred Hutchinson Cancer Research Center

Collaborator: National Cancer Institute (NCI)

Source Fred Hutchinson Cancer Research Center
Brief Summary

This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and donor stem cell transplant followed by cyclosporine, mycophenolate mofetil, and donor lymphocyte infusion in treating patients with hematopoietic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate, and total body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also keep the patient's immune response from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.

Detailed Description

PRIMARY OBJECTIVES: I. To estimate the risk of graft rejection associated with the addition of fludarabine (fludarabine phosphate) to a non-myeloablative conditioning regimen for patients with malignant diseases treatable by allogeneic stem cell transplantation and compare this rate to that observed among patients previously treated without fludarabine. II. To estimate the rate of grade acute II/IV graft-vs-host disease (GVHD) and chronic GVHD in patients treated with low-dose total-body irradiation (TBI), fludarabine, peripheral blood stem cell (PBSC) infusion and immunosuppression with cyclosporine and mycophenolate mofetil. OUTLINE: CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days - 4 to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous transplant within 90 days prior to day 0 will not receive fludarabine phosphate.) PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0. IMMUNOSUPPRESSION: Patients receive cyclosporine orally (PO) twice daily (BID) on days -3 to 35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27. POST TRANSPLANT DONOR LYMPHOCYTE INFUSION (DLI): Patients with stable mixed chimerism on day 56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at higher cell numbers. Up to 6 DLIs may be given 65 days apart. After completion of study treatment, patients are followed up at 4, 6, 12, 18 and 24 months and then annually thereafter.

Overall Status Completed
Start Date 2000-05-01
Primary Completion Date 2005-09-01
Phase Phase 1/Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Risk of graft rejection defined as the absence of detectable peripheral blood donor T cells with the addition of fludarabine phosphate Up to day 56
Incidence of acute grade II/IV GVHD Up to day 90 after the last DLI
Incidence of chronic GVHD Up to 24 months
Secondary Outcome
Measure Time Frame
Incidence of myelosuppression (ANC < 500/ul for > 2 days, platelets < 20,000/ul for > 2 days) after initial PBSC infusion Up to day 56
Response of malignancy to DLI Up to 24 months
Incidence of aplasia after DLI Up to 24 months
Dose of CD3+ cells required to convert mixed to full lymphoid chimeras Up to 24 months
Incidence of non-relapse mortality Up to 24 months
Enrollment 21
Condition
Intervention

Intervention Type: Radiation

Intervention Name: total-body irradiation

Description: Undergo TBI

Arm Group Label: Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)

Other Name: TBI

Intervention Type: Drug

Intervention Name: fludarabine phosphate

Description: Given IV

Arm Group Label: Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)

Intervention Type: Drug

Intervention Name: cyclosporine

Description: Given PO

Arm Group Label: Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)

Intervention Type: Drug

Intervention Name: mycophenolate mofetil

Description: Given PO

Arm Group Label: Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)

Intervention Type: Procedure

Intervention Name: nonmyeloablative allogeneic hematopoietic stem cell transplantation

Description: Undergo allogeneic PBSC transplant

Arm Group Label: Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)

Intervention Type: Biological

Intervention Name: donor lymphocytes

Description: Undergo DLI

Arm Group Label: Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)

Intervention Type: Procedure

Intervention Name: peripheral blood stem cell transplantation

Description: Undergo allogeneic PBSC transplant

Arm Group Label: Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)

Intervention Type: Other

Intervention Name: laboratory biomarker analysis

Description: Correlative studies

Arm Group Label: Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)

Eligibility

Criteria:

Inclusion Criteria: - Patients aged > 49 years and < 75 years with non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and multiple myeloma who are not eligible for a curative autologous transplantation or who have failed prior autologous transplantation; patients with NHL and CLL must have failed prior therapy with an alkylating agent and/or fludarabine, or be at high risk of relapse; patients with multiple myeloma must have stage II or III disease and received prior chemotherapy - Patients < 50 years of age with NHL, CLL or multiple myeloma at high risk of regimen related toxicity through prior autologous transplant or through pre-existing medical conditions - Patients < 75 years of age with other malignant diseases treatable by allogeneic bone marrow transplant (BMT) whom through pre-existing chronic disease affecting kidneys, liver, lungs, and heart are considered to be at high risk for regimen related toxicity using standard high dose regimens; the following diseases are the likely candidates: - Myelodysplastic syndromes - Myeloproliferative syndromes - Acute Leukemia with < 10% blasts - Amyloidosis - Hodgkin's disease - Renal cell carcinoma - Patients with other malignancies declining standard allografts may be approved for transplant following presentation and approval by the Fred Hutchinson Cancer Research Center (FHCRC) chimerism group - DONOR: - Human leukocyte antigen (HLA) genotypically or phenotypically identical related donor - Donor must consent to granulocyte colony-stimulating factor (G-CSF) administration and leukopheresis - Donor must have adequate veins for leukopheresis or agree to placement of central venous catheter (femoral, subclavian) - Age < 75 years Exclusion Criteria: - Eligible for a high-priority curative autologous transplant - Patients with rapidly progressive aggressive NHL unless in minimal disease state - Active central nervous system (CNS) involvement with disease - Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment - Females who are pregnant - Patients who are human immunodeficiency virus (HIV) positive - Cardiac ejection fraction < 40% - Severe defects in pulmonary function testing (defects are currently categorized as mild, moderate and severe) as defined by the pulmonary consultant, or receiving supplementary continuous oxygen - Total bilirubin > 2 x the upper limit of normal - Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) 4 x the upper limit of normal - Karnofsky score < 50 - Patients with poorly controlled hypertension - Patients with renal failure are eligible, however patients with renal compromise (serum creatinine greater than 2.0) will likely have further compromise in renal function and may require hemodialysis (which may be permanent) due to the need to maintain adequate serum cyclosporine levels - DONOR: - Identical twin - Age less than 12 years - Pregnancy - Infection with HIV - Inability to achieve adequate venous access - Known allergy to G-CSF - Current serious systemic illness

Gender:

All

Minimum Age:

N/A

Maximum Age:

74 Years

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
David Maloney Principal Investigator Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Location
Facility:
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Seattle, Washington, 98109, United States
University of Torino | Torino, 10126, Italy
Location Countries

Italy

United States

Verification Date

2020-01-01

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)

Type: Experimental

Description: CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV on days - 4 to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous transplant within 90 days prior to day 0 will not receive fludarabine phosphate.) PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0. IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27. POST TRANSPLANT DLI: Patients with stable mixed chimerism on day 56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at higher cell numbers. Up to 6 DLIs may be given 65 days apart.

Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News